1 / 7

Telaprevir in Treatment Experienced GT-1 PROVE3

Phase 2b. Treatment Experienced. Telaprevir in Treatment Experienced GT-1 PROVE3. McHutchison JG, et al. N Engl J Med. 2010;362:1292-303. Telaprevir for Treatment -Experienced HCV Genotype 1 PROVE3 Study: Study Design.

landman
Télécharger la présentation

Telaprevir in Treatment Experienced GT-1 PROVE3

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Phase 2b TreatmentExperienced Telaprevir in Treatment Experienced GT-1 PROVE3 McHutchison JG, et al. N Engl J Med. 2010;362:1292-303.

  2. Telaprevir for Treatment-Experienced HCV Genotype 1PROVE3 Study: Study Design Drug DosingTelaprevir = 1125 mg loading dose, then 750 mg every 8 hoursPeginterferon alfa-2a = 180 µg weeklyRibavirin = 1000 mg/d for wt < 75 kg; 1200 mg/d for wt > 75 kg Source: McHutchisonJG, et al. N Engl J Med. 2010;362:1292-303.

  3. Telaprevir for Treatment-Experienced HCV Genotype 1PROVE3 Study: Treatment Regimens Week 0 12 24 48 N=115 T12PR24 Telaprevir Peginterferon+ Ribavirin N=113 T24PR48 Telaprevir Peginterferon+ Ribavirin T24P24 N=111 Telaprevir Peginterferon PR48 N=114 Placebo Peginterferon+ Ribavirin Source: McHutchisonJG, et al. N Engl J Med. 2010;362:1292-303.

  4. Telaprevir for Treatment-Experienced HCV Genotype 1PROVE3 Study: Results PROVE3: SVR24 by Regimen SVR = sustained virologic response; T = Telaprevir; P = Peginterferon; PR = Peginterferon + Ribavirin Source: McHutchisonJG, et al. N Engl J Med. 2010;362:1292-303.

  5. Telaprevir for Treatment-Experienced HCV Genotype 1PROVE3 Study: Results Based on Prior History PROVE3: SVR24 by Prior Response Status SVR = sustained virologic response; T = Telaprevir; P = Peginterferon; PR = Peginterferon + Ribavirin Source: McHutchisonJG, et al. N Engl J Med. 2010;362:1292-303.

  6. Telaprevir for Treatment-Experienced HCV Genotype 1PROVE3 Study: Results PROVE3: Adverse Events T = Telaprevir; P = Peginterferon; PR = Peginterferon + Ribavirin Source: McHutchisonJG, et al. N Engl J Med. 2010;362:1292-303.

  7. Telaprevir for Treatment-Experienced HCV Genotype 1PROVE3 Study: Conclusions Source: McHutchisonJG, et al. N Engl J Med. 2010;362:1292-303.

More Related